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Abstract: Cyclophellitol aziridines are potent irreversible in-
hibitors of retaining glycosidases and versatile intermediates
in the synthesis of activity-based glycosidase probes (ABPs).
Direct 3-amino-2-(trifluoromethyl)quinazolin-4(3H)-one-medi-
ated aziridination of l-ido-configured cyclohexene has en-
abled the synthesis of new covalent inhibitors and ABPs of
a-l-iduronidase, deficiency of which underlies the lysosomal
storage disorder mucopolysaccharidosis type I (MPS I). The
iduronidase ABPs react covalently and irreversibly in an ac-
tivity-based manner with human recombinant a-l-iduroni-
dase (rIDUA, Aldurazyme). The structures of IDUA when
complexed with the inhibitors in a non-covalent transition
state mimicking form and a covalent enzyme-bound form
provide insights into its conformational itinerary. Inhibitors
1–3 adopt a half-chair conformation in solution (4H3 and
3H4), as predicted by DFT calculations, which is different from
the conformation of the Michaelis complex observed by
crystallographic studies. Consequently, 1–3 may need to
overcome an energy barrier in order to switch from the 4H3
conformation to the transition state (2,5B) binding conforma-
tion before reacting and adopting a covalent 5S1 conforma-
tion. rIDUA can be labeled with fluorescent Cy5 ABP 2,
which allows monitoring of the delivery of therapeutic re-
combinant enzyme to lysosomes, as is intended in enzyme
replacement therapy for the treatment of MPS I patients.
Introduction
Human a-l-iduronidase (IDUA), which belongs to the GH39
family in the Carbohydrate Active EnZyme (CAZy) classifica-
tion,[1,2] hydrolyzes terminal non-reducing a-l-iduronic acid res-
idues in glycoaminoglycans (GAGs), including dermatan sulfate
(DS) and heparan sulfate (HS), through a two-step Koshland
double-displacement mechanism (Figure 1A).[3–6] The active
site of the enzyme contains a carboxylic acid/carboxylate pair
that acts as an acid/base (Glu188) and a nucleophilic (Glu299)
catalyst. Protonation of the exocyclic oxygen by the acid/base
residue and concomitant nucleophilic attack at the anomeric
carbon by Glu299 leads to SN2 displacement of the aglycon,
yielding a covalent enzyme–substrate complex with inversion
of stereochemistry at the anomeric carbon. In the next step, a
water molecule enters the enzyme active site, where it is de-
protonated by the acid/base (Glu188) and then hydrolyzes the
enzyme–substrate intermediate in a reversal of steps, again
with inversion of anomeric configuration. The conformational
change of IDUA from Michaelis complex to transition state (TS)
and enzyme–inhibitor covalent complex has recently been sug-
gested to follow a 2So!2,5B!5S1 itinerary.[5, 7,8] This catalytic
pathway was predicted on the basis of the structures of Mi-
chaelis complexes with (2R, 3R, 4R, 5S)-2-carboxy-3,4,5-trihy-
droxypiperidine (IdoA-DNJ) and 5-fluoro-a-l-idopyranosyluron-
ic acid fluoride (5F-IdoAF) as reversible inhibitors and the 2-
deoxy-2-fluoro-a-l-idopyranosyluronic (2F-IdoA)–enzyme cova-
lent complex intermediate.
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Mutations in the gene encoding IDUA may result in muco-
polysaccharidosis type I (MPS I), which is a rare autosomal in-
herited recessive disease that leads to toxic accumulation of
HS and DS. MPS I is a devastating disease that affects around 1
in 100,000 individuals and is classified as attenuated MPS I and
more severe MPS I (traditionally categorized from less to more
severe form as Scheie, Hurler–Scheie, or Hurler disease) to dis-
tinguish between disease severity and therapeutic options.[8]
Children with severe MPS I are treated at a young age by he-
matopoietic cell transplantation (HCT).[9] Enzyme replacement
therapy (ERT) with recombinant human a-l-iduronidase
(rIDUA, Aldurazyme) is considered as a treatment for non-neu-
rological manifestations of MPS I.[10] There is consensus among
treating clinicians that the impact of ERT with rIDUA is greatest
when the treatment is initiated early in the disease progres-
sion. An obvious prerequisite for effectiveness is the successful
targeting of infused rIDUA to lysosomes in multiple cell types,
and for this purpose a detailed understanding of rIDUA target-
ing is still urgently needed. Besides MPS I, lysosomal a-l-iduro-
nidase is indirectly involved in two other inherited lysosomal
storage disorders, mucolipidosis II (ML II) and III a/b. Here, a
deficiency in the generation of mannose-6-phosphate (M6P)
moieties in N-linked glycans of newly formed lysosomal en-
zymes impairs their correct routing to lysosomes and therefore
these, including a-l-iduronidase, are largely erroneously secret-
ed.[11]
Herein, we report the synthesis of irreversible IDUA inhibi-
tors and activity-based probes (ABPs) bearing an a-l-iduronic-
configured cyclophellitol aziridine as an electrophilic “war-
head”. Functionalization of the aziridine with a Cy5 fluoro-
phore (for gel and/or cell imaging) or biotin (for chemical pro-
teomics studies) afforded valuable tools (Figure 1B, C) for the
study of a-l-iduronidase in vitro and in situ, structural analysis,
and for monitoring rIDUA uptake and trafficking to lysosomes,
as is revealed here.
Results and Discussion
Synthesis of a-l-iduronic-configured inhibitors and ABPs
Synthetic strategies to assemble cyclophellitol derivatives often
involve different configurations of functionalized cyclohexenes
as starting materials. Based on the synthesis of d-galacto- and
l-fuco-configured cyclohexenes described by Llebaria and co-
workers[12] and our group,[13] we reasoned that reaction of di-
benzylated aldehyde 5[14] with chiral Evans’ oxazolidinone 4
should provide the l-ido-configured cyclohexene by syn-aldol
addition (Figure 2). Indeed, asymmetric aldol condensation cat-
alyzed by dibutylboryl triflate at low temperatures (78 8C to
20 8C) proceeded stereoselectively to provide the desired
aldol product 6 in 60% yield. During the reaction, the non-re-
active terminal alkene derived from isomerization of acrylam-
ide 4 was observed as a major side product. Reduction of oxa-
zolidinone 6 with LiBH4 followed by Grubbs II-catalyzed meta-
thesis afforded the desired l-ido-configured cyclohexene 8 in
excellent yield.
Figure 1. A) Koshland double-displacement mechanism employed by retaining a-l-iduronidase, showing the 2S0!2, 5B!5S1!2, 5B!2S0 conformational reaction
itinerary from the Michaelis complex, transition state 1, covalent substrate–enzyme intermediate, and transition state 2, to the hydrolyzed product. B) Pro-
posed inhibition mechanism of aziridine-based inhibitor 1 and ABPs 2 and 3. C) Chemical structures of a-l-iduronic-configured mechanism-based irreversible
inhibitor 1 and ABPs 2 and 3 described in this work.
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We then attempted olefin aziridination of l-ido-configured
cyclohexene 8 with the specific aim of obtaining the a-stereo-
isomer, and thus potential inhibitors and probes to study
IDUA. Recently, Llebaria and co-workers reported the first N-
aminoaziridine covalent glycosidase inhibitors, which were pre-
pared by stereoselective hydrogen-bonding-guided aziridina-
tion using 3-amino-2-ethylquinazolin-4(3H)-one (Et-Q-NH2).
[12]
Because such hydrogen-bond-mediated aziridination of cyclo-
hexene 8 would generate the undesired b-diastereoisomer, the
free alcohol groups in 8 were benzylated with benzyl bromide
and sodium hydride to generate cyclohexene 9. When the
direct azidirination of 9 was performed with in situ generated
CF3-Q-NHOAc complex, the desired a-aziridine 10 was ob-
tained in 43% yield together with 32% recovered starting ma-
terial (Figure 2). This result implied that hydrogen bonding is
not required for a productive aziridination, provided that the
double bond is freely accessible. Removal of the CF3-Q and
benzyl groups was achieved in one step by Birch reduction
using lithium and liquid ammonia at 78 8C. After quenching
the reaction with H2O, CF3-Q-derived impurities precipitated
and were filtered off. Aziridine 11 was purged of lithium hy-
droxide by cation-exchange chromatography with Amberlite
H+ resin, and the fully deprotected cyclitol aziridine was ob-
tained in 93% yield (Figure 2).
The a-l-configuration of aziridine 11 was established by
1H NMR analysis, and the experimental coupling constants
were compared with the corresponding calculated values ob-
tained from DFT calculations (see the Supporting Information).
Aziridine 11 was then alkylated with 8-azido-1-iodooctane
and K2CO3 or acylated with 8-azidooctanoic acid and EEDQ to
afford intermediates 12 or 13, respectively, which were purified
by reversed-phase column chromatography. Oxidation of C-6
proved to be challenging due to instability of the aziridine
under acidic or basic conditions. Aziridine 1 was obtained in
14% yield by oxoammonium-catalyzed oxidation, maintaining
the reaction and HPLC-MS purification at basic pH. Final click
reaction with Cy5- and biotin-substituted alkynes afforded the
desired ABPs 2 and 3.
In vitro inhibition and labeling of recombinant human a-l-
iduronase with inhibitors 1–3
We examined the inhibition potencies of compounds 1–3 by
incubating them for 60 min with human recombinant a-l-idu-
ronidase (rIDUA, Genzyme) at pH 4.5 in competition with the
fluorogenic substrate 4-methylumbelliferyl-a-iduronide (4-MU-
IdoA). Compounds 1–3 inhibited rIDUA with apparent half-
maximum inhibitory concentrations in the micromolar range
(IC50 values of 1: 40.617.0 mm, 2 : 58.16.66 mm, and 3 :
65.15.73 mm). Intermediate 11 showed no activity, in line
with the role of the carboxylate group at C5 for IDUA binding
in a positively charged enzymatic pocket formed by the
Arg363 and Lys264 side chains and the main-chain NH groups
of Gly305 and Trp306.[8] Surprisingly, alkyl aziridine 12 dis-
played an apparent IC50 of 12.23.24 mm, suggesting that the
carboxylate group may not be essential for binding. These re-
sults are also in line with previous findings that N-alkyl aziri-
dines display improved binding potency towards glycosidases
(Figure S1).[15] rIDUA was labeled by Cy5 ABP 2 in a concentra-
tion- and time-dependent manner, consistent with the irre-
versible inhibition mechanism of these analogues, with optimal
labeling at 50 mm and 120 min incubation, as visualized by
SDS-PAGE (Figure 3A). The optimum pH for labeling with ABP
2 was determined as 4.5–5.0, consistent with the reported op-
timum pH for enzymatic activity (Figure 3B).[2] In addition,
competitive activity-based protein profiling (ABPP) showed
competition in a concentration-dependent manner with 4-MU-
IdoA as well as with inhibitor 1, illustrating the applicability of
this probe for the screening of new inhibitors (Figure 3C). We
also tested the stability of the covalent enzyme–inhibitor com-
plex and observed that rIDUA remained inactivated for at least
100 h (Figure S2).
Figure 2. Synthesis of a-l-iduronic-configured inhibitors and ABPs 1–3. Reagents and conditions: a) DBBT, Et3N, CH2Cl2, 78 8C to 20 8C, 5 h, 60%; b) LiBH4,
THF, rt, 2 h, 99%; c) Grubbs II catalyst, CH2Cl2, 40 8C, 18 h, 98%; d) BnBr, TBAI, NaH, DMF, rt, 18 h, 79%; e) PhI(OAc)2, CH2Cl2, rt, 48 h, 43%; f) Li, NH3, THF,
60 8C, 1 h, 93%; g) 8-azido-1-iodooctane, K2CO3, DMF, 55 8C, 24 h, 12 : 22%; h) TEMPO, NaBr, NaOCl, H2O, 0 8C, 3 h, 14%; i) CuSO4, NaAsc, rt, 18–48 h, 2 : 22%,
3 : 34%.
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We next determined kinetic parameters for rIDUA labeling/
inhibition by ABP 2 at various concentrations (5–60 mm) and
different incubation times (30–150 min) (Figure 3E, F; see also
Figure S3 for SDS-PAGE gels). ABP 2 irreversibly inhibited
rIDUA, with an initial binding constant (KI) of 37.1 mm and an
inactivation rate constant (kinact) of 0.018 min
1, showing this
compound to be a less potent inactivator than other ABPs for
related glycosidases, such as b-glucuronidases[15] (GUSB and
HPSE), b-glucosidases[16,17] (GBA 1, 2, and 3), a-glucosidases[18]
(GAA and GANAB), and a-galactosidase[19] (GLA).
Figure 3. Labeling of rIDUA with ABPs 2 and 3. A) Cy5 ABP 2 labels rIDUA (10 ng) in a concentration-dependent (left, at 4 h incubation time) and time-depen-
dent (right, at 50 mm) manner. Labeling signals were quantified (below each gel image) and fitted with a one-phase association equation. Dotted lines repre-
sent 95% CI. B) ABP 2 labels rIDUA in a pH-dependent manner. The quantified labeling signals were compared to data obtained with 4-MU substrate assay
(below; error range=SD from technical triplicates). C) ABP 2 labels rIDUA and negative controls: without rIDUA, without ABP 2 or with SDS (upper panel),
competition with 4-MU-a-l-iduronide (middle panel) or 1 (lower panel). D) MS/MS pattern of a sample containing rIDUA Asn297–Leu303 active site peptide
labeled with biotin ABP 3 at Glu299, showing peaks corresponding to the detected fragments. Actx=active site peptide. E) Percentages of rIDUA labeling at
different time points and at different concentrations of ABP 2. Data were quantified from three sets of fluorescent gels containing rIDUA labeled with ABP 2
under the depicted conditions to derive a rate constant k for each ABP 2 concentration. F) Left, k vs. [inhibitor] plot. Data were curve-fitted with the Michae-
lis–Menten equation to obtain kinetic parameters. Right, calculated kinetic parameters for ABP 2 labeling of rIDUA. Error range=SD from the three sets.
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Analysis of the covalent ABP 3–IDUA complex by LC-MS/MS
To further demonstrate the covalent binding to the catalytically
active amino acid, we incubated biotinylated ABP 3 with
rIDUA. After chymotryptic digestion and affinity enrichment by
streptavidin beads, the resulting ABP 3-labeled chymotryptic
peptides were analyzed by nanoscale liquid chromatography
coupled with tandem mass spectrometry (nano-LC-MS/MS). A
fragment of the IDUA nucleophile (Glu299) covalently attached
to ABP 3 was detected by MS/MS fragmentation of the 7-
amino-acid peptide containing the nucleophilic residue (Fig-
ure 3D; Figures S5 and S6, and Table S1).
Activity-based protein profiling of IDUA in homogenates of
fibroblasts
We attempted to visualize endogenous IDUA in lysates of cul-
tured normal human dermal fibroblasts (NHDF) and concen-
trated human urine, with and without pre-purification by con-
canavalin A beads. Unfortunately, no clear labeling was ob-
served with ABP 2, and many non-specific bands were detect-
ed by SDS-PAGE that could not be competed by inhibitor 1
nor ABP 3. We compared the specific glycosidase activity and
ABP labeling of b-glucocerebrosidase (GBA) vs. IDUA with
those of the corresponding Cy5 ABPs (ABP JJB367[20] vs. 2) in
recombinant enzymes and human fibroblast lysates (NHDF). It
was observed that while it is theoretically possible to detect
IDUA in fibroblast lysates (calculated amount of endogenous
IDUA was 16 fmol vs. 10 fmol of rIDUA detected by ABP 2), its
detection in NHDF lysates is still challenging due to nonspecif-
ic labeling of other proteins at the required concentration of
ABP 2 (25–50 mm) (Figure S4). Moreover, the calculated amount
of IDUA was 1.5 lower than that of GBA in fibroblast lysates,
which might also hamper IDUA detection (Figure S4). We con-
clude that SDS-PAGE IDUA labeling in cell lysates is not feasible
due to a combination of low abundance of IDUA in the tested
samples and moderate activities of inhibitors 1–3.
Conformations of a-l-ido-aziridine 11 and a-l-idoA-aziridine
by DFT calculations
We studied the conformational preferences of a-l-ido-aziridine
11 and a-l-idoA methylated aziridine as simplified representa-
tions of inhibitors 1–3. A conformer distribution search in Spar-
tan 14[21] and further optimization with Gaussian 09[22] by utiliz-
ing B3LYP/6–311G(d,p)/PCM(H2O) (for details, see the Support-
ing Information) showed that the 4H3 conformation of a-l-ido-
aziridine 11 is greatly favored, with variations in the geometry
about the C5C7 bond (see the Supporting Information). Con-
versely, a-l-idoA-aziridine showed both 4H3 and
3H4 (the latter
1.4 kcalmol1 higher in energy) as relevant conformations. In-
terestingly, the 2,5B boat conformation was also found as a rele-
vant geometry for a-l-idoA-aziridine, albeit with an energetic
cost of 8.0 kcalmol1. In addition, coupling constants (J) were
calculated for the lowest-energy conformations, and these
were in excellent agreement with experimental NMR data (see
the Supporting Information).
Structural analysis of IDUA interactions with inhibitors 1–3
In order to study the mechanism of action of inhibitors 1–3,
we analyzed their conformations upon binding to IDUA by
crystallographic studies. Compounds were applied in solution
for various durations to raIDUA crystals (IDUA recombinantly
expressed in the seeds of a cgl (complex glycan deficient)
mutant of Arabidopsis thaliana ; for details, see the Supporting
Information). Data were collected from a crystal soaked with
ABP 1 for 24 h to 2.02  resolution (Table S2), which revealed
the structure of raIDUA in a covalent complex with 1 (Fig-
ure 4A). The aziridine nitrogen is displaced by nucleophilic
attack of the active site carboxylate to form a trans-2-amino
ester (with the rest of the R group not visible in the electron
Figure 4. Structural insights into raIDUA complexed with ABPs. A) Structure
of raIDUA complexed with a fragment of ABP 1, which is covalently linked
to the nucleophile Glu299. The maximum likelihood/sA weighted 2FobsFcalc
electron density map (gray) is contoured at 1.2 sigma. B) Structure of raIDUA
covalently complexed with a fragment of ABP 1, illustrating the active site
residues that interact with the pseudo-glycoside. C) Structure of raIDUA
complexed with a fragment of ABP 3. The nucleophile Glu299 is shown. The
maximum likelihood/sA weighted 2FobsFcalc electron density map (gray) is
contoured at 1.0 sigma. D) Structure of raIDUA complexed with a fragment
of ABP 3, illustrating the active site residues that interact with the pseudo-
glycoside. E) Superposition of raIDUA covalently complexed with fragments
of ABP 1 (green) and 2F-IdoA (pink; PDB code 4KH2[8]). F) Superposition
(based on alignment of protein main-chain atoms) of raIDUA complexed
with a fragment of ABP 1 (covalent, green) and a fragment of ABP 3 (transi-
tion state, cyan). G) Superposition (based on alignment of C3 and C4 atoms
of each molecule) of raIDUA complexed with a fragment of ABP 1 (covalent,
green), a fragment of ABP 3 (transition state, cyan), and IdoA-DNJ (Michaelis
complex, yellow; PDB code 4KGL).[8]
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density, presumably disordered due to its inherent flexibility;
this region of the structure is exposed to the solvent). Interest-
ingly, the pseudo-glycoside was observed in a 5S1 skew-boat
conformation, which differs slightly from the distorted 2,5B
boat conformation reported for the previously described irre-
versible inhibitor 2-deoxy-2-fluoro-a-l-ido-pyranosyl uronic
acid (2F-IdoA) covalently bound to IDUA.[8] The observed 5S1
conformation of the covalent inhibitor 1–enzyme complex sup-
ports predictions for the conformational itinerary followed by
a-iduronidase GH39 (Figure 1A).[7] The carboxylate group of
the pseudo-iduronic acid forms bidentate hydrogen bonds
with the main-chain nitrogen atoms of Gly305 and Trp306, the
C4 hydroxyl group forms hydrogen bonds with Arg363 and
Asp349, the C3 hydroxyl group interacts with Asp349 and a
water molecule, and the C2 hydroxyl group forms hydrogen
bonds with Asn181 and the nucleophile Glu299 (Figure 4B).
In the covalent complex between IDUA and 2F-IdoA, the nu-
cleophile Glu299 is rotated by around 908 compared to the po-
sition observed in the complex here with the fragment of 1,[8]
and the fluoro group at C2 may preclude an interaction with
Oe2 of Glu299, causing it to rotate. However, the inhibitor 1–
IDUA complex presented here, bearing a hydroxyl group at C2
and showing an interaction with Glu299, is more likely to rep-
resent what occurs during catalysis (Figure 4E). In an attempt
to fully define the conformational inhibition of compounds 1–
3, raIDUA crystals were soaked with the ABPs for shorter dura-
tions. Data collected to 2.39  resolution (Table S2) on a crystal
soaked with ABP 3 for 45 min revealed electron density in the
active site of raIDUA consistent with the unreacted cyclophelli-
tol aziridine 3 (Figure 4C). A methyl group on the cyclophellitol
aziridine was visible, but the rest of the R group was not evi-
dent and presumably disordered. Interestingly, the pseudo-gly-
coside was observed in a 2,5B conformation, which is the pre-
dicted transition state for GH39 a-l-iduronisase.[7] The majority
of the interactions with active site residues were the same as
those described for the covalent complex with raIDUA (Fig-
ure 4D), although a shift in position of the glycoside indicated
that the carboxylate group additionally interacted with Lys264.
The hydroxyl group at C2 forms a hydrogen bond with the nu-
cleophile Oe2 of Glu299, but at a surprisingly short distance of
2.4 , suggesting a tight interaction. This close proximity re-
sults in a distance between the pseudo-anomeric carbon and
Oe1 of only 2.9 . These tight interactions, together with the
2,5B conformation of the pseudo-glycoside, suggest that we are
observing the pseudo-glycoside at the transition state; such
structural observations are rare using wild-type enzymes, but
here it was possible due to the slow inactivation kinetics of 3.
The importance of the interaction between the glycoside and
the C2 hydroxyl group supports work by others;[23,24] indeed,
interactions at the 2-position were estimated to contribute
18 kJmol1 binding energy to stabilization of the transition
state for a b-glucosidase during the glycosylation step of the
catalysis.[23] Based on this work, it was postulated that a hydro-
gen bond formed between the C2 hydroxyl group and the nu-
cleophile would be optimal at the transition state, as the two
groups come into close proximity during formation of the co-
valent glycosyl–enzyme bond.[23]
Superimposition of the main-chain atoms for the two com-
plexes revealed a shift in the position of the cyclophellitol aziri-
dine to accommodate formation of the covalent bond (Fig-
ure 4F). This engendered movement of between 0.2 and 0.4 
at C5, C4, and C3, 0.5  at C2, 0.6  at the carbon at the posi-
tion of the endocyclic oxygen, and 1.1  at the pseudo-ano-
meric carbon. These structures, together with the previously
reported structure of IDUA complexed with the inhibitor IdoA-
DNJ, in which the pseudo-glycoside was observed in a 2S0 con-
formation (predicted Michaelis complex conformation), allow
the full conformational itinerary for IDUA to be structurally de-
fined. The structures of IDUA with IdoA-DNJ (Michaelis com-
plex) and 3 (transition state complex) and the fragment of ABP
1 (covalent complex) were overlapped at the C3 and C4 atoms
(Figure 4G). This clearly shows the electrophilic migration from
the Michaelis complex in a 2S0 conformation, through the tran-
sition state in a 2,5B conformation, to the covalent intermediate
in a 5S1 conformation. At the pseudo-anomeric carbon, there is
a displacement of 0.74  on going from the Michaelis complex
to the covalent intermediate. This is accompanied by a small
(0.23 ) movement at C2, but larger movement at C5 (0.72 )
and the atom at the position of the endocyclic oxygen
(0.70 ), presumably to bring about the required migration at
the anomeric position.
rIDUA visualization by confocal fluorescence microscopy
Finally, we investigated whether ABP 2 could be used to study
rIDUA cellular uptake and lysosomal internalization. The majori-
ty of therapeutic glycosidases are modified with mannose 6-
phosphate (M6P) residues for their recognition by M6P recep-
tors (MPRs) on the plasma membrane and consequent trans-
port to the lysosomes. In order to track rIDUA within cells,
NHDF and fibroblasts of MPS I and ML II patients were fed with
pre-labeled rIDUA-ABP 2, and the samples were analyzed by
confocal fluorescence microscopy (Figure 5). After incubation
for 16 h, points of fluorescence were observed within the lyso-
somes, indicating rIDUA lysosomal uptake by all of the ana-
lyzed fibroblast models. However, this was extinguished when
the sample was pre-incubated with M6P, which blocks M6P re-
ceptors (Figure 5, right). This result clearly indicates that rIDUA
lysosomal uptake is mediated by MPRs,[25] and that ABP 2 can
be used to study the trafficking and localization of rIDUA
within cells in MPS I and ML II patient cell lines.
Conclusions
In conclusion, we have synthesized a-l-ido-configured cyclo-
phellitol aziridine, which is a key intermediate for generation
of the first a-l-iduronidase ABPs. Key a-l-ido-configured cyclo-
hexene 8 could be an interesting starting point for the devel-
opment of new IDUA inhibitors or chaperones. With the inhibi-
tors described herein, we have conducted ABPP studies on
rIDUA, showing that ABP 2 irreversibly labels rIDUA in a con-
centration- and time-dependent manner, with optimum label-
ing at pH 4.5–5. We have further demonstrated covalent rIDUA
inhibition by nano-LC-MS/MS, detecting a 7-amino-acid pep-
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tide fragment of rIDUA containing the nucleophilic residue
bound to ABP 3.
The conformations can strongly influence the inhibitory po-
tencies and selectivities of cyclophellitol analogues.[26] Inhibi-
tors 1–3 are slower binders than the corresponding cyclophel-
litol aziridine conformers (such as b-gluco-aziridine ABP JJB367
for GBA[20]). DFT calculations have shown that inhibitors 1–3
adopt mainly a half-chair conformation (4H3 and
3H4) in solu-
tion, with the 2,5B conformation also as relevant geometry at
an extra cost of 8.0 kcalmol1. Crystallographic studies have
shown that compounds 1–3 bind IDUA in a 2,5B boat confor-
mation in the Michaelis complex. The half-chair conformations
(4H3 and
3H4) of inhibitors 1–3, as predicted by DFT calculations,
differ from any of the reaction itinerary conformations of a-l-
iduronidase depicted in Figure 1A, and thus inhibitors 1–3
may need to overcome this 8.0 kcalmol1 energetic barrier to
adopt the Michaelis complex transition state (2,5B) conforma-
tion. Therefore, we propose that the lower potency of a-l-
idoA-aziridine analogues is a manifestation of this energetic
barrier. We have also provided structural evidence for covalent
addition of the ABPs to the nucleophilic residue of raIDUA. In
the process, we have defined the conformation of the cyclo-
phellitol aziridine at the transition state and in the covalent in-
termediate, which supports predictions concerning the confor-
mational itinerary followed by a-l-iduronidase. The insights
gained through these studies should help in the design of
closer conformational 2,5B analogues by the use of different
electrophilic traps or reactive species for the generation of im-
proved inhibitors or molecular chaperones, with the end goal
being the future provision of improved therapies for MPS I pa-
tients. Although IDUA labeling with ABP 2 in complex biologi-
cal samples was not successful due to the lower potency of
this analogue compared with previously reported glycosidase
probes, we have demonstrated that ABP 2 can be used to
study the localization and trafficking of rIDUA within cultured
cells, and have shown that the rIDUA–ABP 2 complex is recog-
nized by MPRs and internalized in lysosomes.
Experimental Section
See the Supporting Information for experimental details.
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